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LETTER TO THE EDITOR
An overview of published results from randomized studies of nitrosoureas
in primary high grade malignant glioma
Sir - The prognosis of patients with high-grade malignant Table I Studies giving survival rates as a measure of treatment
glioma is poor. Despite improve results following effect
radiotherapy after neurosurgery, the median survival time is
about 9 months, and the proportion of 2-year survivors Number ofpatients
about 5-10%. Dose Control+
Studies involving the use of adjuvant chemotherapy have Author Nitrosourea (MgM2) Control nitrosourea
been conducted, but the results from individual studies have
not yet established its role in the management of the disease. Solero et al. (1979) CCNU or 130 or 32 70
As a preliminary exercise in designing a new MRC trial, BCNU 240
we recently carried out an overview of published results from SGSG (1985) CCNU 120 118 126
randomised studies of nitrosoureas in primary high-grade Walker et at. (1980) BCNU or 240 or 94 183
malignant glioma. Our intention was to assess the effect of a MeCCNU 220
nitrosourea, given adjuvant to radiotherapy, on survival. Brisman et al. (1976) CCNU or 100 or 16 17
A literature search using 'Medline' and 'Cancerlit' BCNU or 200 or
identified over 200 references on therapy for brain tumours, MeCCNU 150
since 1975. Of these, we isolated the randomised trials of Walker et al. (1978) BCNU 240 93 100
high-grade gliomas with chemotherapy, in which the control Chang et al. (1983) BCNU 240 148 165
group received surgery and radiotherapy, and the treatment EORTC (1978) CCNU 130 11 8
group, chemotherapy adjuvant to surgery and radiotherapy. Gat t I (1978) CCNU 100 37 37
Thirteen such studies were found, and in 10 of these, the
chemotherapy was a single agent nitrosourea. Six of these 10
studies reported survival times, two relapse-free intervals and
two, both. We decided to use survival rates as our measure Table II Radiotherapy regimes
of treatment effect, and the 8 studies giving this information
are listed in Table I. The dose of CCNU in the studies Author Radiotherapy
ranged between 100-130mgm-2 per cycle, for BCNU the
range was 200-240mgm-2, and for Methyl-CCNU, 150- Solero et al. (1979) 50Gy/5 weeks
MgM-2 -8 weeks SGSG (1985) 40Gy/5 weeks/10 fractions 220mgm -. In each1 case, th1e cycle length1 was 6-w wee(s or 50Gy/5 weeks/20 fractions (Table I). The radiotherapy regimes employed in the various Walker et al. (1980) 60Gy/6-7 weeks/20-35 fractions
studies did not differ greatly, being generally between 5,000 Brisman et al. (1976) 3OGy/3 weeks to brain
and 6,000cGy (Table II). +30Gy/3 weeks to tumour
We looked at survival rates at 6, 12, 18 and 24 months in Walker et al. (1978) 5OGy/5-6 weeks/25-30 fractions
each treatment group, and calculated an overall difference Chang et al. (1983) 60Gy/7 weeks/35 fractions
weighted in a manner which takes into account the size of EORTC (1978) 55-60Gy
each trial. The results at 12 and 24 months are summarised Garret et at. (1978) 45Gy/4 weeks
in Table III. The overall differences at 12 and 24 months
were statistically significant - approximately 9% better
survival in the nitrosourea patients at 12 months (P=0.002) and carrying the most weight in the overview - were
and 3.5% at 24 months (P=0.046). organised by the BTSG (2 studies, (Walker et al., 1978;
There are some important limitations to these data - 1980), the Scandinavian Glioblastoma Study Group (SGSG,
firstly, the problem of publication bias - positive results are 1985), and one jointly by the RTOG and the ECOG (Chang
more likely to be published than negative results - and we et al., 1983), and we have some reason to believe that these
have used only published studies. However, the 4 largest - large cooperative groups publish their results regardless of
Table III Results at 12 and 24 months
12 month survival (%) 24 month survival (%)
Control+ Control+
Author Control nitrosourea Diff Control nitrosourea Diff.
Solero (1979) 40 61 +21 17 17 0
SGSG (1985) 45 45 0 9 7 --2
Walker et at. (1980) 35 43 ±8 10 14 +4
Brisman et at. (1976) 31 35 +4 25 5 -20
Walker et at. (1978) 24 32 +8 1 5 +4
Changetal.(1983) 35 45 +10 15 21 +6
EORTC (1978) 6 49 ±43 0 22 +22
Garretetal.(1978) 34 51 +17 16 42 ±26
Overall difference + 8.8 + 3.4
Standard error 2.8 1.7
Z(Pvalue) 3.1 (0.002) 2.0 (0.046)90 LETTER TO THE EDITOR
outcome. Secondly, incomplete data meant we had to omit
some trials, while several of those used gave survival
information in graphical form, from which we had to read
the survival rates. An assumption we had to make in
calculating standard errors was that all patients had
complete follow-up, which was inlikely to be uniformly true.
Finally, we have no measure of the quality of life of these
patients.
We would conclude that there is evidence, admittedly
limited, that a course of nitrosourea only, given adjuvant to
radiotherapy, does increase survival of high-grade glioma
patients by a small amount. The challenge is to find a
chemotherapy combination which will enhance this apparent
improvement.
Yours, etc.,
S.P. Stenning, L.S. Freedman, N.M. Illeehen
MRC Cancer Trials Office and Clinical Oncology and
Radiotherapeutics Unit,
MRC Centre, Hills Road, Cambridge, CB2 2QH, UK.
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